Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 4, 2013, Pages

  Le Bras, Maëlle ^a,b   Roquilly, Antoine ^a   Deckert, Valérie ^c   Langhi, Cédric ^a   Feuillet, Fanny ^d   Sébille, Véronique ^d   Mahé, Pierre Joachim ^a   Bach, Kalyane ^a   Masson, Damien ^a   Lagrost, Laurent ^c   Costet, Philippe ^a   Asehnoune, Karim ^a   Cariou, Bertrand ^a,b  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b CHU de Nantes   (France)

^c UNIVERSITÉ DE BOURGOGNE   (France)

^d UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NORADRENALIN; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; PROTEINASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; CHOLESTEROL BLOOD LEVEL; CONTINUOUS INFUSION; CONTROLLED STUDY; CRITICAL ILLNESS; DISEASE MARKER; DRUG USE; FEMALE; HUMAN; INJURY SEVERITY; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTIPLE TRAUMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; TRAUMATIC BRAIN INJURY; TREATMENT DURATION;

ADULT; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; CRITICAL ILLNESS; FEMALE; HUMANS; HYDROCORTISONE; INFUSION PUMPS; INTENSIVE CARE UNITS; MALE; PLACEBOS; PROGNOSIS; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; SEVERITY OF ILLNESS INDEX; TRAUMA SEVERITY INDICES; WOUNDS AND INJURIES;

EID: 84876268347     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-4236     Document Type: Article

References (20)

1. Carpentier YA, Scruel O. Changes in the concentration and composition of plasma lipoproteins during the acute phase response. Curr Opin Clin Nutr Metab Care. 2002; 5:153-158.
2. Khovidhunkit W, Kim MS, Memon R.A., et al Effectsofinfection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 2004; 45:1169-1196.
3. Gui D, Spada PL, De Gaetano A, Pacelli F. Hypocholesterolemia and risk of death in the critically ill surgical patient. Intensive Care Med. 1996; 22:790-794.
4. Messotten D, Swinnen JV, Vanderhoydonc F, Wouters P.J., Van den Berghe G. Contribution of circulating lipids to the improved outcome of critical illness by glycemic control with intensive insulin therapy. J Clin Endocrinol Metab. 2004; 89:219-226.
5. Buttenschoen K, Berger D, Strecker W., et al Association of endo-toxemia and production of antibodies against endotoxins after multiple injuries. J Trauma. 2000; 48:918-923.
6. Van Leeuwen P.A., Boermeester MA, Houdjik A.P., et al Clinical significance of translocation. Gut. 1994; 35(1 suppl):S28-S34.
7. Costet P, Krempf M, Cariou B. PCSK9 and LDL cholesterol: unravelling the target to design the bullet. Trends Biochem Sci. 2008; 33:426-434.
8. Lakoski SG, Lagace TA, Cohen J.C., Horton JD, Hobbs HH Plasma levels of PCSK9 in a large multiethnic population. J Clin Endocrinol Metab. 2009; 94:2537-2543.
9. Vergès B., Duvillard L, Brindisi M.C., et al Lack of association be-tween plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes. Atherosclerosis. 2011; 219:342-348.
10. Abifadel M, Varret M, Rabès JP, et al Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003; 34: 154-156.
11. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006; 354:1264-1272.
12. McKenney JM, Koren MJ, Kereiakes D.J., Hanotin C., Ferrand AC, Stein EA Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/ REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012; 59: 2344-2353.
13. Roquilly A, Mahe PJ, Seguin P, et al Hydrocortisone therapy for patients with multiple trauma: the randomized controlled HY-POLYTE study. JAMA. 2011; 305:1201-1209.
14. Cariou B, Le Bras M, Langhi C, et al Association between plasma PCSK9 and 7-glutamyl transferase levels in diabetic patients. Atherosclerosis. 2010; 211:700-702.
15. Chien JY, Jerng JS, Yu C.J., Yang PC Low serum level of high-density lipoprotein is a poor prognostic factor for severe sepsis. Crit Care Med. 2005; 33:1688-1693.
16. Feingold KR, Moser AH, Shigenaga J.K., Patzek SM, Grunfeld C. Inflammation stimulates the expression of PCSK9. Biochem Bio-phys Res Commun. 2008; 374:341-344.
17. Jeong HJ, Lee HS, Kim K.S., Kim YJ, Yoon D, Park SW 2008 Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 by sterol regulatory element binding-protein 2. J Lipid Res. 2008; 49:399-409.
18. Li L, Thompson PA, Kitchens RL Infection induces a positive acute phase apolipoprotein E response from a negative acute phase gene: role of hepatic LDL receptors. J Lipid Res. 2008; 49:1782-1793.
19. Ulevitch RJ, Johnston AR The modification of biophysical and endotoxic properties of bacterial lipopolysaccharides by serum. J Clin Invest. 1978; 62:131-124.
20. Cariou B, Ouguerram K, Zaïr Y, et al PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypo-betalipoproteinemia. Arterioscler Thromb Vasc Biol. 2009; 29: 2191-2197.